Lake Street Rates Kazia Therapeutics (KZIA) buy, $32 Price Target
Lake Street maintains a buy rating on Kazia Therapeutics, setting a price target of $32, a 153.77% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Lake Street rated Kazia Therapeutics Limited ($KZIA) "buy" with a $32 price target on June 11, 2026.
Since the rating, $KZIA is up 10.5% after 1 week, up 8.4% after 1 month and down 42.2% to date (from the $12.54 close on Jun 11, 2026).
KZIA
Kazia Therapeutics Limited
Key Points
- On June 11, 2026, Lake Street reiterated its buy rating on Kazia Therapeutics (NasdaqCM: KZIA) with a price target of $32, while the stock trades at $12.61.
- The company's stock is currently well below its 52-week high of $17.40, suggesting potential upside if the company meets its targets.
- Kazia Therapeutics, focused on oncology, has a strong buy consensus among analysts, with a mean price target of approximately $28.80.
Get $KZIA trade alerts by text
We text you when insiders, Congress or big funds trade $KZIA. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Kazia Therapeutics Limited alert may contain errors. Disclosures
Lake Street's Confident Stance on Kazia Therapeutics
On June 11, 2026, Lake Street reiterated its buy rating on Kazia Therapeutics (NasdaqCM: KZIA) and set a price target of $32. The stock closed at $12.61 on that day, indicating significant upside potential based on Lake Street's target. This reaffirms the firm's confidence in Kazia’s future prospects as it develops innovative oncology treatments.
Analysts Set New Price Targets
Analysts have shown continued support for Kazia Therapeutics, with several recent actions reflecting a positive outlook. On September 10, 2026, BTIG reiterated its buy rating with a target price of $40, maintaining its previous target. Earlier, on September 1, BTIG also maintained its buy rating but increased the target from $34 to $40, showcasing their growing confidence in the company. Meanwhile, Canaccord Genuity initiated coverage with a buy rating and a target of $29 on August 13, 2026. These consistent ratings highlight a strong bullish sentiment towards Kazia within the analyst community.
Stock Performance Context
Kazia's stock is currently trading well below its 52-week high of $17.40, suggesting that there's room for growth if the company can deliver on its clinical trials and strategic plans. The stock's performance, trading around its 50-day moving average of $12.83, presents a unique opportunity for potential investors, especially given the optimistic ratings it has received from analysts.
$KZIA price target
Kazia Therapeutics Limited daily closes and this analyst's $32 target. Not advice.
Insider Buying and Selling at Kazia Therapeutics Limited
In a sign of confidence from company leadership, Chief Financial Officer James Levine purchased 200,000 shares of Kazia Therapeutics on June 19, 2026. While the transaction details indicate a price of $0.00, it reflects a commitment to the company's future and aligns with the positive sentiment expressed in analyst ratings. Levine's purchase is noteworthy as it comes soon after Lake Street’s reaffirmation of their buy rating, signaling internal belief in the company's direction.
Future Outlook
As Kazia Therapeutics prepares for its next earnings report on May 28, 2025, investors will likely keep a close eye on the company's progress in its ongoing clinical trials. The recent analyst ratings and insider purchases may signal a growing confidence in the company’s ability to deliver results, making it a stock to watch in the coming months. Remember, the reiteration of ratings, like Lake Street's on Kazia, reflects past holdings as of the reporting date and may not represent current positions.
Related Filing Alerts
Source: Lake Street's rating change on $KZIA (Jun 11, 2026). Written by software, not financial advice. How we make alerts